Victor M Tang1,2, Jessica Lam-Shang-Leen3, Thomas D Brothers4, Keith Hansen1, Alexander Caudarella1, Wiplove Lamba1, Tim Guimond1. 1. Mental Health and Addictions Service, St. Michael's Hospital, Toronto, Ontario, Canada. 2. Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. 3. Department of Medicine, Clinical Pharmacology and Toxicology, University of Toronto, Ontario, Canada. 4. Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Abstract
BACKGROUND: Prerequisite opioid withdrawal symptoms prior to buprenorphine induction are unacceptable to many patients. We assessed whether transdermal buprenorphine minimized withdrawal while bridging to sublingual therapy among hospital inpatients. METHODS: Retrospective chart review of (n = 23) inpatients with opioid use disorder or opioid dependence due to chronic pain. RESULTS: Of 23 inpatients, 65% transitioned without symptoms, while 35% experienced mild withdrawal. Ninety-six percent completed planned hospitalizations, with 83% engaged in treatment 4 weeks post-discharge. DISCUSSION AND CONCLUSIONS: Bridging to sublingual therapy with transdermal buprenorphine patches was feasible without withdrawal symptoms. SCIENTIFIC SIGNIFICANCE: This strategy may facilitate buprenorphine therapy in hospital inpatients. (Am J Addict 2019;00:1-4).
BACKGROUND: Prerequisite opioid withdrawal symptoms prior to buprenorphine induction are unacceptable to many patients. We assessed whether transdermal buprenorphine minimized withdrawal while bridging to sublingual therapy among hospital inpatients. METHODS: Retrospective chart review of (n = 23) inpatients with opioid use disorder or opioid dependence due to chronic pain. RESULTS: Of 23 inpatients, 65% transitioned without symptoms, while 35% experienced mild withdrawal. Ninety-six percent completed planned hospitalizations, with 83% engaged in treatment 4 weeks post-discharge. DISCUSSION AND CONCLUSIONS: Bridging to sublingual therapy with transdermal buprenorphine patches was feasible without withdrawal symptoms. SCIENTIFIC SIGNIFICANCE: This strategy may facilitate buprenorphine therapy in hospital inpatients. (Am J Addict 2019;00:1-4).
Authors: Cheryl Teruya; Robert P Schwartz; Shannon Gwin Mitchell; Albert L Hasson; Christie Thomas; Samantha H Buoncristiani; Yih-Ing Hser; Katharina Wiest; Allan J Cohen; Naomi Glick; Petra Jacobs; Paul McLaughlin; Walter Ling Journal: J Psychoactive Drugs Date: 2014 Nov-Dec
Authors: Sarah E Wakeman; Joshua P Metlay; Yuchiao Chang; Grace E Herman; Nancy A Rigotti Journal: J Gen Intern Med Date: 2017-05-19 Impact factor: 5.128
Authors: Christopher W Shanahan; Donna Beers; Daniel P Alford; Eileen Brigandi; Jeffrey H Samet Journal: J Gen Intern Med Date: 2010-03-17 Impact factor: 5.128
Authors: Laura R Marks; Satish Munigala; David K Warren; Stephen Y Liang; Evan S Schwarz; Michael J Durkin Journal: Clin Infect Dis Date: 2019-05-17 Impact factor: 9.079
Authors: Victoria D Powell; Jack M Rosenberg; Avani Yaganti; Claire Garpestad; Pooja Lagisetty; Carol Shannon; Maria J Silveira Journal: JAMA Netw Open Date: 2021-09-01
Authors: Nicholas Avery; Amy G McNeilage; Fiona Stanaway; Claire E Ashton-James; Fiona M Blyth; Rebecca Martin; Ali Gholamrezaei; Paul Glare Journal: BMJ Date: 2022-04-04